Trial Profile
Effect of SYN-004 (ribaxamase) on the Diversity of the Gut Microbiome in Patients Receiving Intravenous Ceftriaxone Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Oct 2017
Price :
$35
*
At a glance
- Drugs Ceftriaxone (Primary) ; Ribaxamase (Primary)
- Indications Clostridium difficile infections
- Focus Therapeutic Use
- 23 Oct 2017 New trial record
- 08 Oct 2017 Results presented at the IDWeek 2017